

Asthma Innovation Research

Annual Report

and Financial Statements

for the Year Ended 1 January 2023

Asthma Innovation Research

(Registration number 1168495)

Contents

	<u>Page</u>
Reference and Administrative Details	3
Trustees' Report	4
Statement of Trustees' Responsibilities	7
Statement of Financial Activities	8
Balance Sheet	10
Notes to the Financial Statements	11 to 16

Asthma Innovation Research

(Registration number 1168495)

Reference and Administrative Details

Charity name	The legal name is “Asthma Innovation Research”
Charity Registration Number	1168495 Registered with Charity Commission in England & Wales
Companies House registration	CE007169 Charitable Incorporated Organisation “CIO” Registered with Companies House in England & Wales
Legal structure	Governing document is the Trust Deed establishing the charity. The trustees are all individuals.
Trustees	Dr Jonny Coppel Dr Rahul Chodhari (Chairman) Dr Simon Braithwaite Dr Dominic Fenn Dr Lucy Everson Dr Jessica Kearney
Principal address	Apartment 55 Warwick Building 366 Queenstown Road London SW11 8NJ
Website and Email	www.asthmainnovationresearch.co.uk Jonny.coppel@gmail.com asthmainnovationresearch@gmail.com
Bankers	Metro Bank plc Southampton Row, London
Custodian trustees holding assets	There are no assets held by any custodian trustee or nominee on behalf of the charity

Asthma Innovation Research

(Registration number 1168495)

Trustees' Report

The trustees present the annual report together with the financial statements of the charity for the year ended 1 January 2023.

Objects and activities of the charity

The purposes of the charity are set out in its governing document.

The charity's governing document is a constitution that was drawn up and was approved by the Charity Commission upon registering on 28 July 2016.

The main purpose of Asthma Innovation Research (AIR) as set out by our governing document is to relieve sickness and promote good health by reducing mortality and morbidity due to asthma, in particular in the child population, in particular but not exclusively by:

- (1) training medical students to educate school children, parents and other members of the community about asthma and increase their knowledge of asthma emergency protocols;
- (2) promoting the discussion, the consideration of, and research into matters of asthma;
- (3) publishing results of research and discussion on matters of asthma;
- (4) hosting educational events including, but not limited to, conferences and lectures on topics of importance; and
- (5) providing opportunities to encourage the exchange of ideas.

The main activities undertaken in relation to those purposes during the year.

The main activities undertaken in relation to these purposes are:

- (1) Managing the asthma teaching programmes currently set up in University College London medical school, Cardiff University, Imperial College University, King's College London University and now established at Cambridge University. These projects involve training medical students to go into primary and secondary schools and teach school children about asthma to reduce the stigma around the condition and to improve knowledge of the condition and the emergency protocols.
- (2) Attempting to set up the teaching programmes in more medical schools.
- (3) The distribution and advertising of asthma educational booklets that we had previously developed.

Asthma Innovation Research

(Registration number 1168495)

- (4) Investigating opportunities to improve the awareness of other medical conditions in the community using the template that we have created.

The main activities undertaken during the year to further the charity's purpose for the public benefit.

The trustees have had regard to the Charity Commission's guidance on public benefit in managing the activities of the charity.

The charity's main objectives and achievements for the year

In this time period we had the following achievements:

- (1) The project continues to offer both virtual and face to face sessions for the schools and continue to receive excellent feedback from teachers and students.
- (2) We have taught approximately 800 school children nationally. The project remains in place at 4 universities (UCL, KCL, Imperial and Cardiff) and after a successful pilot, is now established at Cambridge University.
- (3) In 2022 we continued the Asthmanauts project in Camden and Islington boroughs. We increased uptake of the booklets to 83% of GP practices and redistributed further materials to school nurses of Camden. We have received further excellent feedback from the professionals using the booklets, particularly nursing staff in GPs and schools. We continue to monitor downloads from our website and encourage online use via social media. The Asthmanauts booklet has been updated and is now part of the National Asthma Toolkit. We have had contact from communities outside of London looking to use the Asthmanauts booklet.
- (4) Project Health Resilience is an education- and youth-setting based health literacy pilot delivered by doctors and health professionals for young Londoners aged 16 – 19 years. The project was initially conceived in 2019 by Dr Leonora Weil and Astrid Grindlay, at that time working in the Public Health team at Camden Council, in partnership with the Camden Learning team. Following earlier collaboration with AIR and Camden Public Health for a separate programme, Dr Jonny Coppel (AIR) introduced Dr Clovis Rau and Dr Carys Lewis for session development and facilitation in late 2020. The project has since expanded to a wider multi-stakeholder team involving clinicians and staff from the UK Health Security Agency, NHS Trusts, and the London School of Hygiene and Tropical Medicine. It is currently part of, and funded by, NHS England's Legacy and Health Equity Partnership (where Leonora and Astrid are now based, in line with the agenda of reducing inequalities in immunisations, screening and access to health). The programme encompasses bespoke health literacy modules, developed by a multi-disciplinary team of doctors and public health professionals, and covers the following topics: emergency first aid for young people; health literacy; mental health resilience; and screening and immunisations. These modules are

Asthma Innovation Research

(Registration number 1168495)

delivered by frontline NHS clinicians and public health professionals who specialise in these topic areas.

Adolescence is a key stage of transition at which young people need to begin to recognise health issues and to independently engage with health services and access appropriate help. Supporting young people at this critical stage is key in empowering them to be able to take control of their own health in future. Experience from the pandemic has also shown us how vital it is to build trust between young people and health professionals.

Over the past 12 months, up until January 2023, the project has expanded from an initial pilot in one Camden school, to wider settings across the capital, and has reached hundreds of learners including reaching care leavers and more vulnerable young people. Clinical Fellows in Emergency Medicine, Public Health and Mental Health have been appointed. We have collaborated with Peer Outreach Workers and the Greater London Assembly, and youth organisations such as Thrive LDN and The Hive, to ensure that the sessions are co-produced with young people. We are in the process of enrolling a wider team of clinicians and health professionals as 'Project Health Resilience Ambassadors', as the project expands. The Project Health Resilience Team are hoping to complete data collection for the initial evaluation towards the end of the year, and exploring possibilities for sustainable models of the project for the future.

The contribution of volunteers during the year.

Volunteers, in terms of the Trustees and others have regularly given their time and resources during this period with no drain on the charity's funding.

Financial Review

The financial position of the charity at 1 January 2023 and comparatives for the prior period, as more fully detailed in the accounts, can be summarised as follows:-

	2023	2022
	£	£
Net income/(expenditure)	<u>(388)</u>	<u>(312)</u>
Unrestricted revenue funds for general purposes of the charity	2,232	2,620
Restricted funds	-	-
Total Funds	<u>2,232</u>	<u>2,620</u>

There was no income generated during the financial year 2022/2023, compared to £4,300 raised in the previous 2021/22 year.

Asthma Innovation Research

(Registration number 1168495)

On 1/1/23, AIR had £2,232, which comprises general funds, and there were no restricted funds. There are no concerns about the charity's ability to continue. These unrestricted funds of £2,232 should drive the schools programme forward and will aid the continuing distribution campaign of Princess Asma and Asthmanauts.

Outlook for 2023

Our main areas of activity in 2023 are predicted to be:

1. The Schools Education Project. We will continue to offer sessions where possible either face to face or virtually. As always, we will continue to try to spread the project to new medical schools, targeting Oxford University in particular.
2. The further distribution of Asthmanauts will be reviewed.
3. Investigating changing our constitution to enable us to use our educational templates to improve the lives of people suffering from other medical conditions aside from asthma.
4. The yoga fundraising series will be recontinued once feasible.

Statement of Trustees' Responsibilities

The trustees are responsible for preparing the trustees' report and the financial statements in accordance with the United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and applicable law and regulations.

The law applicable to charities requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:


- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

Asthma Innovation Research

(Registration number 1168495)

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the applicable Charities (Accounts and Reports) Regulations, and the provisions of the constitution. The trustees are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by the trustees of the charity on 30/8/2023 and signed on its behalf by:



.....
Dr Jonny Coppel
Trustee



.....
Dr Lucy Everson
Trustee

Asthma Innovation Research

(Registration number 1168495)

Statement of Financial Activities (including Income & Expenditure Account) for the Year Ended 1 January 2023

	SORP	Current Year			Prior Year
	Ref	Unrestricted	Restricted	Total	Total
		Funds	Funds	Funds	Funds
		£	£	£	£
Income & Endowments from:					
Donations & Legacies	A1	-	-	-	4,300
Charitable activities	A2	-	-	-	-
Other trading activities	A3	-	-	-	-
Investments	A4	-	-	-	-
Other	A5	-	-	-	-
Total income	A	-	-	-	4,300
Expenditure on:					
Raising funds	B1	-	-	-	-
Charitable activities	B2	388	-	388	4,612
Other	B3	-	-	-	-
Total Expenditure	B	388	-	388	4,612
Net income/(expenditure) for the year	A-B	(388)	-	(388)	(312)
Reconciliation of funds:-	E				
Total funds brought forward		2,620	-	2,620	2,932
Total funds carried forward		2,232	-	2,232	2,620

The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.

The statement of financial activities includes all gains and losses in the year. All incoming resources and resources expended derive from continuing activities.

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities.

The notes attached on pages 11 to 16 form an integral part of these accounts.

Asthma Innovation Research

(Registration number 1168495)

Analysis of prior year total funds, as required by paragraph 4.2 of the SORP

	SORP Ref	Unrestricted Funds 2022 £	Prior Year Restricted Funds 2022 £	Total Funds 2022 £
Income & Endowments from:				
Donations & legacies	A1	73	9,755	9,828
Expenditure on:				
Raising funds	B1	-	-	-
Charitable activities	B2	-	8,784	8,784
Total expenditure	B	-	8,784	8,784
Net income for the year		73	971	1,044
Net movement in funds		73	971	1,044
Reconciliation of funds:-	E			
Total funds brought forward		1,888	-	1,888
Total funds carried forward		1,961	971	2,932

The statement of financial activities includes all gains and losses in the year. All incoming resources and resources expended derive from continuing activities.

The notes attached on pages 11 to 16 form an integral part of these accounts.

Asthma Innovation Research


(Registration number 1168495)

Balance Sheet as at 1 January 2023

	Note	SORP Ref	2023 £	2022 £
Current assets		B		
Debtors	7	B2	-	-
Cash at bank and in hand		B4	2,232	2,620
Creditors: Amounts falling due within one year	8	C1	-	-
The total net assets of the charity			2,232	2,620
Funds of the charity:				
Unrestricted funds		D3	2,232	2,620
Restricted funds			-	-
Total funds	9		2,232	2,620

The 'SORP Ref' indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA.

Approved by the trustees of the charity on 30/8/2023 and signed on its behalf by:



.....
Dr Jonny Coppel
Trustee



.....
Dr Lucy Everson
Trustee

The notes attached on pages 11 to 16 form an integral part of these accounts.

Asthma Innovation Research

(Registration number 1168495)

Notes forming part of the Financial Statements for the year ended 1 January 2023

1 Accounting policies

The principal accounting policies are summarised below. The accounting policies have been applied consistently throughout the year and in the preceding year.

Statement of compliance

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

Basis of preparation

Asthma Innovation Research meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

Exemption from preparing a cash flow statement

The charity opted to early adopt Bulletin 1 published on 2 February 2016 and have therefore not included a cash flow statement in these financial statements.

Going concern

The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern.

Income and endowments

Voluntary income including donations, gifts, legacies and grants that provide core funding or are of a general nature is recognised when the charity has entitlement to the income, it is probable that the income will be received and the amount can be measured with sufficient reliability.

Donations and legacies

Donations and legacies are recognised on a receivable basis when receipt is probable, and the amount can be reliably measured.

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a

Asthma Innovation Research

(Registration number 1168495)

basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use. Other support costs are allocated based on the spread of staff costs.

Raising funds

These are costs incurred in attracting voluntary income, the management of investments and those incurred in trading activities that raise funds.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Grant provisions

Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty about either the timing of the grant or the amount of grant payable.

Governance costs

These include the costs attributable to the charity's compliance with constitutional and statutory requirements, including audit, strategic management and trustees' meetings and reimbursed expenses.

Taxation

The charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

Research and development

Research and development expenditure is written off as incurred.

Trade debtors

are amounts due from customers for merchandise sold or services performed in the ordinary course of business are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of is established when there is objective evidence that they will not be able to collect all amounts due according to the original terms of the receivables.

Asthma Innovation Research

(Registration number 1168495)

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees' discretion in furtherance of the objectives of the charity. Designated funds are unrestricted funds earmarked by the trustees for particular purposes.

Restricted funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal.

Financial instruments

Classification

Financial assets and financial liabilities are recognised when the charity becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charity after deducting all of its liabilities.

Recognition and measurement

All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets and liabilities are only offset in the statement of financial position when, and only when there exists a legally enforceable right to set off the recognised amounts and the charity intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Financial assets are derecognised when and only when a) the contractual rights to the cash flows from the financial asset expire or are settled, b) the charity transfers to another party substantially all of the risks and rewards of ownership of the financial asset, or c) the charity, despite having retained some, but not all, significant risks and rewards of ownership, has transferred control of the asset to another party.

Asthma Innovation Research

(Registration number 1168495)

Financial liabilities are derecognised only when the obligation specified in the contract is discharged, cancelled, or expires.

Fair value measurement

The best evidence of fair value is a quoted price for an identical asset in an active market. When quoted prices are unavailable, the price of a recent transaction for an identical asset provides evidence of fair value as long as there has not been a significant change in economic circumstances or a significant lapse of time since the transaction took place. If the market is not active and recent transactions of an identical asset on their own are not a good estimate of fair value, the fair value is estimated by using a valuation technique.

2 Income from donations and legacies

	Unrestricted	Restricted	Total 2022	Total 2021
	£	£	£	£
Donations and legacies:				
Donations from individuals	-	-	-	1,450
Other donations	-	-	-	2,850
Regular giving and capital donations	-	-	-	-
	-	-	-	4,300

3 Expenditure on raising funds

There were no costs incurred in generating the donations and voluntary income.

4 Expenditure on charitable activities

	Unrestricted	Restricted	Total 2023	Total 2022
	£	£	£	£
Governance costs	-	-	-	-
Costs of charitable activities	388	-	388	4,612
	388	-	388	4,612

Asthma Innovation Research

(Registration number 1168495)

During the year, costs were incurred on website maintenance. In the prior year, the costs of charitable activities related to printing materials and other resources acquired during 2021/22, together with the distribution of all of the remaining restricted funds to Whittington Health Charity.

5 Trustees remuneration and expenses

No trustees, nor any persons connected with them, have received any remuneration from the charity during the year.

6 Taxation

The charity is a registered charity and is therefore exempt from taxation.

7 Debtors

No debtors were outstanding at the end of the financial year.

8 Creditors: amounts falling due within one year

No creditors were outstanding at the end of the financial year.

9 Funds

	Balance at 2 January 2021	Incoming resources	Resources expended	Balance at 1 January 2023
Unrestricted funds				
General	2,620	-	388	2,232
<hr/>				
	Balance at 2 January 2021	Incoming resources	Resources expended	Balance at 1 January 2022
Restricted funds				
General	-	-	-	-
<hr/>				

Asthma Innovation Research

(Registration number 1168495)

10 Analysis of net assets between funds

	General Funds	Designated Funds	Restricted Funds	Total Funds
Current assets	2,232	-	-	2,232
Net assets at 1 January 2023	2,232	-	-	2,232

11 Analysis of net funds

	At 2 January 2022 £	Cash flow £	At 1 January 2023 £
Cash at bank and in hand	2,620	(388)	2,232
Net funds	2,620	(388)	2,232